专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2763563A4 MOBILE DEVICE CASE WITH RETRACTOR REEL ASSEMBLY FOR USER-PROVIDED HEADPHONES 有权
标题翻译：住房与用户的卷筒组装耳机移动设备
公开(公告)号：EP2763563A4
公开(公告)日：2015-03-25
申请号：EP12838154
申请日：2012-09-24
申请人： KOENIG SCOTT , CONROY DAVID
发明人： KOENIG SCOTT , CONROY DAVID
IPC分类号： A45C11/00 , B65H75/44 , H01R13/72 , H02G11/02 , H04B1/38 , H04M1/15
CPC分类号： H05K5/0247 , B65H75/4431 , B65H75/4449 , B65H2701/3919 , H01R13/72 , H02G11/02 , H04M1/15 , H04R1/1033 , H05K5/0217

2. 发明申请

WO2013052303A3 MOBILE DEVICE CASE WITH RETRACTOR REEL ASSEMBLY FOR USER-PROVIDED HEADPHONES 审中-公开
标题翻译：带有退磁头组件的移动设备外壳用于用户提供的耳机
公开(公告)号：WO2013052303A3
公开(公告)日：2013-06-13
申请号：PCT/US2012056970
申请日：2012-09-24
申请人： KOENIG SCOTT , CONROY DAVID
发明人： KOENIG SCOTT , CONROY DAVID
IPC分类号： A45C11/00 , H04B1/38
CPC分类号： H05K5/0247 , B65H75/4431 , B65H75/4449 , B65H2701/3919 , H01R13/72 , H02G11/02 , H04M1/15 , H04R1/1033 , H05K5/0217
摘要： A mobile device case includes a reel assembly, including a reel, a supporting plate, and a hub between the reel and the supporting plate. The hub includes a first cavity between the hub and the supporting plate for housing a spring, and a second cavity between the hub and the reel for housing a flat flexible cable (FFC). The spring is wound in a first direction, while the FFC is wound in a second direction. The FFC includes a first end for electrically coupling to a female jack connector of a device. A female connector is electrically coupled to a second end of the FFC for engaging a male jack connector of user-provided headphones. When the reel rotates in the first direction, the spring tightens and the FFC loosens. When the reel rotates in the second direction, the spring loosens and the FFC tightens.
摘要翻译：移动设备壳体包括卷轴组件，包括卷轴，支撑板以及在卷轴和支撑板之间的轮毂。毂包括在毂和用于容纳弹簧的支撑板之间的第一空腔，以及在毂和卷轴之间的用于容纳扁平柔性电缆（FFC）的第二腔。弹簧沿第一方向缠绕，而FFC沿第二方向缠绕。 FFC包括用于电耦合到装置的母插座连接器的第一端。母连接器电耦合到FFC的第二端，用于接合用户提供的耳机的公插头连接器。当卷轴沿第一方向旋转时，弹簧拉紧，FFC松动。当卷轴沿第二个方向旋转时，弹簧松开，FFC拉紧。

3. 发明申请

WO2008140603A3 METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FC?R ACTIVATING AND FC?R INHIBITING 审中-公开
标题翻译：使用具有更改功能的FC区域的免疫球蛋白治疗疾病的方法用于FC？R激活和FC？R抑制
公开(公告)号：WO2008140603A3
公开(公告)日：2009-04-23
申请号：PCT/US2007086793
申请日：2007-12-07
申请人： MACROGENICS INC , STAVENHAGEN JEFFREY B , KOENIG SCOTT
发明人： STAVENHAGEN JEFFREY B , KOENIG SCOTT
IPC分类号： A61K38/00
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2887 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an Fc?R that activates a cellular effector ("Fc?Ractivating," such as Fc?RIIA or Fc?RIIIA) and an Fc?R that inhibits a cellular effector ("Fc?Rinhibiting" such as Fc?RIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such Fc?R for the Fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by Fc?R is desired (e.g., inflammation, autoimmunde disease).
摘要翻译：本发明涉及使用分子，特别是多肽，特别是包含变体Fc区的免疫球蛋白（例如抗体）治疗或预防癌症和其它疾病的方法，其中所述变体Fc区包含至少一个相对于野生型Fc区，该变体Fc区结合激活细胞效应子（“FcγRactivation”，例如FcγRIIA或FcγRIIIA）的FcγR和抑制细胞效应子（Fc）的FcγR 抑制野生型免疫球蛋白Fc区的FcγR的相对结合亲和力的改变的亲和力比例如FcγRIIA。本发明的方法特别可用于预防，治疗或改善与需要由FcγR介导的效应细胞功能的增强功效的疾病，病症或感染相关的一种或多种症状（例如，癌症，感染性疾病）或由FcγR介导的受抑制的效应细胞应答是期望的（例如炎症，自身免疫疾病）。

4. 发明申请

WO2007147090A3 METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY 审中-公开
标题翻译：使用具有降低毒性的单克隆抗体治疗自身免疫性疾病的方法
公开(公告)号：WO2007147090A3
公开(公告)日：2008-10-16
申请号：PCT/US2007071275
申请日：2007-06-14
申请人： MACROGENICS INC , KOENIG SCOTT , WILDER RONALD , BONVINI EZIO , JOHNSON LESLIE S , PILLEMER STANLEY
发明人： KOENIG SCOTT , WILDER RONALD , BONVINI EZIO , JOHNSON LESLIE S , PILLEMER STANLEY
IPC分类号： A61K39/395 , A61K39/21 , A61K39/40
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/41 , C07K2317/71
摘要： The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译：本发明提供治疗，预防，减缓T细胞介导的免疫疾病，特别是自身免疫疾病（例如，自身免疫性糖尿病（即1型糖尿病或胰岛素依赖型糖尿病（IDDM））的症状的进展或改善的方法，以及多发性硬化）通过使用抗人CD3抗体。本发明的本发明的抗体优选用于低剂量给药方案，慢性给药方案或方案，其涉及在一段时间后再次进行。本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。此外，本发明的方法提供使用经修饰的抗人CD3抗体，使得与未修饰的抗人CD3抗体相比，它们表现出降低或消除的效应子功能和T细胞活化。

5. 发明申请

WO2006066078A3 FC?RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译： FC？RIIB-特异性抗体及其使用方法
公开(公告)号：WO2006066078A3
公开(公告)日：2006-10-19
申请号：PCT/US2005045586
申请日：2005-12-15
申请人： MAGROGENICS INC , KOENIG SCOTT , VERI MARIA CONCETTA , TUAILLON NADINE
发明人： KOENIG SCOTT , VERI MARIA CONCETTA , TUAILLON NADINE
IPC分类号： C07K16/00 , A01N63/00 , A61K39/395 , C07H21/04 , C07K1/00 , C12N15/00
CPC分类号： A61K39/00 , A61K2039/505 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of Fc?RIIB, particularly human Fc?RIIB, and block the Fc binding site of human Fc?RIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
摘要翻译：本发明涉及与FcγRIIB特别是人FcγRIIB的细胞外结构域特异性结合并阻断人FcγRIIB的Fc结合位点的抗体或其片段。本发明提供了通过施用本发明的抗体来增强免疫应答来治疗癌症和/或调节免疫复合物介导的细胞活化的方法。本发明还提供了通过施用本发明的抗原 - 抗体复合物和抗体来破坏对抗原的耐受性的方法。

6. 发明申请

WO2007009064A3 METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY 审中-公开
标题翻译：使用具有降低毒性的免疫抑制性单克隆抗体治疗自身免疫性疾病的方法
公开(公告)号：WO2007009064A3
公开(公告)日：2009-04-23
申请号：PCT/US2006027386
申请日：2006-07-11
申请人： MACROGENICS INC , KOENIG SCOTT , WILDER RONALD , BONVINI EZIO , JOHNSON LESLIE S
发明人： KOENIG SCOTT , WILDER RONALD , BONVINI EZIO , JOHNSON LESLIE S
IPC分类号： A61K39/395 , A61P37/02
CPC分类号： C07K16/2809 , A61K38/28 , A61K2039/505 , C07K2317/24 , C07K2317/524 , C07K2317/53 , C07K2317/71 , A61K2300/00
摘要： The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non- modified anti-CD3 antibodies.
摘要翻译：本发明提供了通过使用抗CD3抗体来治疗，预防或改善T细胞介导的免疫疾病，特别是自身免疫性疾病的症状的方法。特别地，本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。另外，本发明提供抗CD3抗体的修饰，使得它们与非修饰抗CD3抗体相比表现出降低或消除的效应子功能和T细胞活化。

7. 发明申请

WO2008118324A2 COMPOSITION AND METHOD OF TREATING CANCER WITH AN ANTI-UROPLAKIN IB ANTIBODY 审中-公开
标题翻译：抗UROPLAKIN抗体治疗癌症的组合物和方法
公开(公告)号：WO2008118324A2
公开(公告)日：2008-10-02
申请号：PCT/US2008003635
申请日：2008-03-20
申请人： MACROGENICS INC , FERGUSON STACY , KOENIG SCOTT , TUAILLON NADINE , JOHNSON LESLIE S , HUANG LING , RANKIN CHRISTOPHER
发明人： FERGUSON STACY , KOENIG SCOTT , TUAILLON NADINE , JOHNSON LESLIE S , HUANG LING , RANKIN CHRISTOPHER
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/72 , C07K2317/732 , C07K2319/30
摘要： This invention provides antibodies that specifically recognize and bind to UPK-Ib. Also included are diagnostic and therapeutic assays directed to diseases associated with unregulated levels of UPK-Ib using said antibodies. The antibodies and derivatives thereof can also be useful in the diagnisic and/or treatment of cancer associated with abnormal expression of UPK-Ib.
摘要翻译：本发明提供了特异性识别和结合UPK-1b的抗体。还包括使用所述抗体针对与未调节水平的UPK-Ib相关的疾病的诊断和治疗测定。该抗体及其衍生物也可用于诊断和/或治疗与UPK-1b异常表达相关的癌症。

8. 发明申请

WO2007117600A3 COMBINATION THERAPY FOR TREATING AUTOIMMUNE DISEASES 审中-公开
标题翻译：治疗自身免疫性疾病的组合疗法
公开(公告)号：WO2007117600A3
公开(公告)日：2008-08-14
申请号：PCT/US2007008579
申请日：2007-04-06
申请人： MACROGENICS INC , KOENIG SCOTT
发明人： KOENIG SCOTT
IPC分类号： A61K39/395
CPC分类号： C07K16/2809 , A61K2039/507 , C07K16/2887
摘要： A combination therapy comprising administering to a subject in need of an effective therapeutic treatment for an autoimmune disease, a T cell antibody that is capable of modulating the activation of a T cell response to an antigen presenting cell in combination with a B cell antibody. The combination therapy may provide improved clinical benefits to a subject in need of treatment by reducing the circulating and tissue levels of B cells while providing immunosuppression of T cell activation, thus modulating the immune response to self antigens.
摘要翻译：一种联合疗法，其包括对需要对自身免疫性疾病进行有效治疗的受治疗者，能够调节与B细胞抗体组合的抗原呈递细胞的T细胞应答活化的T细胞抗体。联合治疗可以通过减少B细胞的循环和组织水平来提供需要治疗的受试者的改善的临床益处，同时提供T细胞活化的免疫抑制，从而调节对自身抗原的免疫应答。

9. 发明申请

WO2008079713A9 METHODS FOR THE TREATMENT OF LADA AND OTHER ADULT-ONSET AUTOIMMUNE DIABETES USING IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY 审中-公开
标题翻译：用降低毒性的免疫抑制性单克隆抗体治疗LADA和其他成人发作自身免疫性糖尿病的方法
公开(公告)号：WO2008079713A9
公开(公告)日：2008-10-23
申请号：PCT/US2007087394
申请日：2007-12-13
申请人： MACROGENICS INC , KOENIG SCOTT
发明人： KOENIG SCOTT
CPC分类号： C07K16/2809 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/71
摘要： The present invention provides methods of treating, preventing or ameliorating the symptoms of Latent Autoimmune Diabetes in Adults (LADA) and adult-onset type 1 diabetes through the use of anti-human CD3 antibodies. In particular, in invention provides methods of preventing or delaying insulin requirement in patients diagnosed with LADA. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-human CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译：本发明提供了通过使用抗人CD3抗体来治疗，预防或改善成人隐匿性自身免疫糖尿病（LADA）和成人发病1型糖尿病的症状的方法。具体而言，本发明提供了在被诊断患有LADA的患者中预防或延迟胰岛素需求的方法。本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，从而调节与自身免疫病相关的T细胞介导的细胞毒性。此外，本发明提供了修饰抗人CD3抗体，使得与未修饰的抗人CD3抗体相比，它们表现出减少的或消除的效应子功能和T细胞活化。

10. 发明申请

WO9951188A3 A POLYPEPTIDE COMPRISING THE AMINO ACID OF AN N-TERMINAL CHOLINE BINDING PROTEIN A TRUNCATE, VACCINE DERIVED THEREFROM AND USES THEREOF 审中-公开
标题翻译：包含N-末端醇结合蛋白A三肽的氨基酸的多肽，其衍生的疫苗及其用途
公开(公告)号：WO9951188A3
公开(公告)日：2001-04-19
申请号：PCT/US9907669
申请日：1999-04-07
申请人： ST JUDE CHILDRENS RES HOSPITAL , MEDIMMUNE INC , TUOMANEN ELAINE I , MASURE H ROBERT , WIZEMANN THERESA M , JOHNSON LESLIE SYDNOR , KOENIG SCOTT
发明人： TUOMANEN ELAINE I , MASURE H ROBERT , WIZEMANN THERESA M , JOHNSON LESLIE SYDNOR , KOENIG SCOTT
IPC分类号： C12N15/00 , A61K38/00 , A61K39/00 , A61K39/09 , A61K39/395 , A61K48/00 , A61P11/00 , A61P31/04 , C07K14/315 , C07K16/12 , A61K39/40
CPC分类号： C07K14/3156 , A61K38/00 , A61K39/00
摘要： This invention provides an isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1,3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides isolated polypeptides comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A truncate. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of N-terminal choline binding protein A truncate. Lastly, this invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use.
摘要翻译：本发明提供了一种分离的多肽，其包含N-末端胆碱结合蛋白A截短物的氨基酸序列，其中氨基酸序列在SEQ ID NO：1,3-7或9-11中任一项所述，包括片段，突变体，变体，类似物或衍生物。此外，本发明提供了分离的多肽，其包含N-末端胆碱结合蛋白A截短物的氨基酸序列，其中所述氨基酸在SEQ ID NO：24中列出，其中所述多肽保留其天然三级结构和制备方法。本发明提供了分离的多肽，其包含N-末端胆碱结合蛋白A截短物的氨基酸序列，其中所述多肽具有凝集素活性并且不与胆碱结合。本发明提供了分离的免疫原性多肽，其包含N-末端胆碱结合蛋白A截短体的氨基酸序列。本发明提供编码包含N-末端胆碱结合蛋白A截短物的氨基酸序列的多肽的分离的核酸。最后，本发明提供药物组合物，疫苗以及诊断和治疗使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式